Brown David M

Brunstetter Tyson J, Zwart Sara R, Brandt Keith, Brown David M, Clemett Simon J, Douglas Grace L et al.

A severe SANS case in an astronaut with genetic predispositions showed significant ocular changes and improvement, possibly linked to B-vitamin supplementation or reduced CO2, highlighting potential interventions for spaceflight-induced vision issues.

Brown David M, Laswell Stephen M, Rahman Effie Z, Fan Kenneth C, Shah Ankoor, Patel Sagar B et al.

This study developed a new OCT-based PVD staging system, finding PVD progresses predictably with age, and Stage C (partial separation) is a high-risk stage for vitreoretinal traction, aiding clinical assessment and surgical planning.

Kar Sudeshna Sil, Abraham Joseph, Wykoff Charles C, Sevgi Duriye Damla, Lunasco Leina, Brown David M et al.

This study linked computational imaging features from UWFA/OCT in DME to cytokine levels, finding strong correlations between VEGF and imaging biomarkers, which could personalize anti-VEGF treatment.

Abraham Joseph R, Wykoff Charles C, Arepalli Sruthi, Lunasco Leina, Yu Hannah J, Hu Ming et al.

This study linked aqueous cytokines and OCT biomarkers in DME to anti-VEGF response, finding baseline VEGF/MCP-1 predict anatomical outcomes, aiding prognosis.

Campochiaro Peter A, Channa Roomasa, Berger Brian B, Heier Jeffrey S, Brown David M, Fiedler Ulrike et al.

MP0112, a novel anti-VEGF drug, showed prolonged vision and edema improvement in DME patients, but initial formulations caused inflammation. Impurities were identified and removed for future trials.

Campochiaro Peter A, Nguyen Quan Dong, Hafiz Gulnar, Bloom Steven, Brown David M, Busquets Miguel et al.

This study compared FAc inserts and implants, finding implants deliver higher, more sustained aqueous drug levels. Levels above 1 ng/ml increase glaucoma risk, informing treatment choices.

Brown David M, Heier Jeffrey S, Clark W Lloyd, Boyer David S, Vitti Robert, Berliner Alyson J et al.

Intravitreal aflibercept significantly improved vision in CRVO-related macular edema, with benefits maintained at one year with PRN dosing, offering an effective treatment option.

Campochiaro Peter A, Brown David M, Pearson Andrew, Chen Sanford, Boyer David, Ruiz-Moreno Jose et al.

Sustained-delivery FAc inserts significantly improved vision in DME patients for 3 years, especially those with chronic DME, despite increased cataract and glaucoma surgery risk, offering a valuable long-term treatment option.

Campochiaro Peter A, Hafiz Gulnar, Shah Syed Mahmood, Bloom Steven, Brown David M, Busquets Miguel et al.

This study found Iluvien inserts provide sustained fluocinolone acetonide release, improving vision in DME patients for a year, with the 0.5 µg/day dose showing better efficacy and mild IOP elevation.

Brown David M, Michels Mark, Kaiser Peter K, Heier Jeffrey S, Sy Judy P, Ianchulev Tsontcho

In neovascular AMD, ranibizumab significantly outperformed verteporfin PDT over two years, improving visual acuity and anatomical outcomes, establishing it as a superior treatment.